Viking Therapeutics (VKTX) Enters $12.5M Stock Purchase Agreement with Aspire Capital
- AT&T (T) Agrees to Acquire Time Warner (TWX) for More than $80 Billion - WSJ
- Top 10 News for 10/17 - 10/21: Merger Rumors Abound; CEOs Depart; Tesla Kicks Autopilot Up A Notch
- Wall Street ends little changed; Microsoft hits record
- AT&T (T) in Advanced Talks to Acquire Time Warner (TWX) - DJ
- Rockwell Automation (ROK) Said to Attract Takeover Interest from Schneider Electric - Source
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Viking Therapeutics, Inc. (Nasdaq: VKTX) announced it has entered into a $12.5 million common stock purchase agreement with Aspire Capital Fund, LLC ("Aspire Capital").
Under the terms of the agreement, Aspire Capital has made an initial purchase of $500,000 of Viking common stock at $1.50 per share, which represents a 15% premium over the August 24 closing price of $1.31. In addition, after the Securities and Exchange Commission (SEC) declares the registration statement related to the transaction effective, Aspire Capital has committed to purchase up to an additional $12.0 million in shares of common stock over the next 30 months at prices based on the market price at the time of each sale. No warrants, derivatives, or other share classes are associated with this agreement. Proceeds from the stock purchase agreement will be used for general corporate purposes, including advancing the company's drug development pipeline.
"This agreement with Aspire Capital, a long-term, healthcare-focused institutional investor, provides Viking with increased flexibility as we enter an important period for the company and our development pipeline," said Brian Lian, Ph.D., chief executive officer of Viking. "The initial stock sale to Aspire Capital, as well as the group's commitment to further investment over the next 30 months, offers the potential to significantly extend our runway as we advance our Phase 2 clinical programs for VK5211 in hip fracture and VK2809 in hypercholesterolemia and fatty liver disease."
"We are very pleased to enter into this agreement with Viking, a company that we believe is well-positioned to succeed in becoming a leader in metabolic and endocrine disorder drug development," commented Steven G. Martin, Managing Member of Aspire Capital. "In an effort to support the advancement of Viking's rich pipeline, we are excited to make this initial investment, as well as provide the company with a flexible and efficient source of capital. In particular, we are looking forward to Phase 2 data for VK5211 and VK2809 next year. Also, we are very enthusiastic about the potential of VK0214 in X-ALD based on the pre-clinical results announced in late July."
Under the terms of the common stock purchase agreement, Viking will control the timing and amount of any sale of shares of common stock to Aspire Capital. Aspire Capital has no right to require any sales by Viking but is obligated to make purchases according to Viking's direction, as governed by the purchase agreement. There are no limitations on the use of proceeds, financial covenants or restrictions on future financings and there are no rights of first refusal, participation rights, penalties or liquidated damages in the purchase agreement. Viking maintains the right to terminate the purchase agreement at any time, at its discretion, without any additional cost or penalty.
Viking also entered into a registration rights agreement with Aspire Capital in connection with its entry into the purchase agreement that requires Viking to file a registration statement regarding the shares sold to Aspire Capital. A complete and detailed description of the purchase agreement and related registration rights agreement is set forth in Viking's Current Report on Form 8-K, filed today with the SEC.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- NYSE to Suspend Trading in MGT Capital Investments (MGT); Will Move to Delist
- Short-Seller Hits Back Against Banc of California (BANC); Threatens to Release 'Thousands' of Pages of Documents
- Organovo (ONVO) Prices 9M Share Stock Offering for Proceeds of $25M
Create E-mail Alert Related CategoriesCorporate News, Equity Offerings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!